News on Maxim Pharmaceuticals Incorporated from BioPortfolio.com http://www.BioPortfolio.com Consolidated Maxim Pharmaceuticals Incorporated news from BioPortfolio.com Wed, 10 Feb 2010 13:14:24 GMT en Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038960&HITNO=0&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038960&THISHREF=http://c.moreover.com/click/here.pl%3fz2537852243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038960&HITNO=0&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038960&THISHREF=http://c.moreover.com/click/here.pl%3fz2537852243%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSmartBrief: Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038931&HITNO=1&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038931&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038931&HITNO=1&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038931&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838958%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: News and FDA Updates for IMS Health (NYSE:RX), Incyte (Nasdaq:INCY), Ligand (NASDAQ:LGND)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040265&HITNO=2&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040265&THISHREF=http://c.moreover.com/click/here.pl%3fz2538680663%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4040265&HITNO=2&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4040265&THISHREF=http://c.moreover.com/click/here.pl%3fz2538680663%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comAmerican Chronicle: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041705&HITNO=3&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041705&THISHREF=http://c.moreover.com/click/here.pl%3fz2539210806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041705&HITNO=3&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041705&THISHREF=http://c.moreover.com/click/here.pl%3fz2539210806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041749&HITNO=4&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041749&THISHREF=http://c.moreover.com/click/here.pl%3fz2539219766%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041749&HITNO=4&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041749&THISHREF=http://c.moreover.com/click/here.pl%3fz2539219766%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire via Yahoo!: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041738&HITNO=5&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041738&THISHREF=http://c.moreover.com/click/here.pl%3fz2539217696%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041738&HITNO=5&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041738&THISHREF=http://c.moreover.com/click/here.pl%3fz2539217696%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinanzNachrichten.de: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041707&HITNO=6&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041707&THISHREF=http://c.moreover.com/click/here.pl%3fz2539211171%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041707&HITNO=6&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041707&THISHREF=http://c.moreover.com/click/here.pl%3fz2539211171%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041700&HITNO=7&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041700&THISHREF=http://c.moreover.com/click/here.pl%3fz2539209690%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041700&HITNO=7&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041700&THISHREF=http://c.moreover.com/click/here.pl%3fz2539209690%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038929&HITNO=8&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038929&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838669%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038929&HITNO=8&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038929&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838669%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Ligand Pharmaceuticals Incorporated Q4 2009 Earnings Call Transcripthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036985&HITNO=9&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036985&THISHREF=http://c.moreover.com/click/here.pl%3fz2536855824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036985&HITNO=9&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036985&THISHREF=http://c.moreover.com/click/here.pl%3fz2536855824%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSeeking Alpha: Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035243&HITNO=10&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035243&THISHREF=http://c.moreover.com/click/here.pl%3fz2536163912%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035243&HITNO=10&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035243&THISHREF=http://c.moreover.com/click/here.pl%3fz2536163912%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036884&HITNO=11&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036884&THISHREF=http://c.moreover.com/click/here.pl%3fz2536813000%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4036884&HITNO=11&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4036884&THISHREF=http://c.moreover.com/click/here.pl%3fz2536813000%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Ligand Pharmaceuticals (LGND) Tops Q4 EPS by 3c on Strong Revenues; Guides for 2010http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035713&HITNO=12&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035713&THISHREF=http://c.moreover.com/click/here.pl%3fz2536339539%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035713&HITNO=12&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035713&THISHREF=http://c.moreover.com/click/here.pl%3fz2536339539%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStreet Insider: Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035289&HITNO=13&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035289&THISHREF=http://c.moreover.com/click/here.pl%3fz2536185463%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035289&HITNO=13&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035289&THISHREF=http://c.moreover.com/click/here.pl%3fz2536185463%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Resultshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035267&HITNO=14&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035267&THISHREF=http://c.moreover.com/click/here.pl%3fz2536176351%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4035267&HITNO=14&MSIZE=503&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Maxim%20Pharmaceuticals%20Incorporated&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4035267&THISHREF=http://c.moreover.com/click/here.pl%3fz2536176351%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: